MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations

Kangaslampi and Zijlmans frame MDMA-assisted psychotherapy (MDMA-AP) as a combined pharmacological and psychotherapeutic approach that has completed adult Phase III trials for PTSD and may soon receive regulatory approval for adults. They note that many adolescents experience potentially traumatic events and a substantial minority develop persistent PTSD; although several trauma-focused psychological treatments for young people (for example TF-CBT, PE-A, NET/KIDNET, and developmentally adapted CPT) produce large average improvements, a non-trivial proportion of adolescents either drop out or fail to respond adequately. Given these limitations, the authors argue it is timely to consider whether MDMA-AP might offer an alternative or adjunctive option for adolescents with PTSD. The paper sets out to provide a rationale for studying MDMA-AP in adolescents aged roughly 14–17, to suggest possible adaptations to the psychotherapeutic component if MDMA-AP were to be used with this age group, and to highlight risks and ethical considerations that may be specific to minors. The authors restrict their focus to PTSD specifically and emphasise the need for empirical clinical trials rather than extrapolating adult results to adolescents by default.

The extracted text does not report a formal methods section or a systematic search strategy; instead, the paper is a narrative, conceptual review and rationale drawing on published adult MDMA-AP trials, evidence-based trauma-focused treatments for adolescents, preclinical literature, and epidemiological data on adolescent trauma and PTSD. Kangaslampi and Zijlmans synthesise findings from these literatures to identify potential mechanisms by which MDMA could augment psychotherapy and to derive candidate adaptations for adolescent care. Scope and boundaries are specified: the discussion is limited to older adolescents (approximately 14–17 years) and to MDMA-AP as a treatment for PTSD. The authors compare and contrast the existing MDMA-AP treatment manual (which emphasises a largely non-directive, flexible psychotherapeutic approach) with structured trauma-focused protocols used in adolescent populations, and use these comparisons to motivate suggested changes. Preclinical animal studies and adult safety data are also reviewed to highlight evidence gaps and safety questions relevant to minors. The paper does not present new primary data or meta-analytic pooling; it instead proposes hypotheses and practical considerations for future clinical research.

Kangaslampi and Zijlmans assemble evidence and argument under three main headings: the rationale/potential benefits of MDMA-AP for adolescents, specific adaptations to the psychotherapeutic component that may be needed for this age group, and potential risks peculiar to adolescents. Rationale and potential benefits: The authors note that over half of adolescents encounter at least one potentially traumatic event before age 18, and between 5% and 25% of exposed youth develop enduring PTSD. Existing trauma-focused treatments yield large average symptom reductions, yet around 11% of minor participants drop out in carefully conducted trials and between a quarter to half of participants can fail to respond adequately. Drawing on adult MDMA-AP trials, the paper identifies five ways MDMA might augment PTSD treatment for adolescents: (1) reducing avoidance and enabling trauma processing by dampening anxiety and negative emotional reactivity; (2) facilitating reappraisal of maladaptive beliefs about the self and the world; (3) enhancing fear extinction and disrupting fear memory reconsolidation, thereby potentially accelerating symptom relief; (4) strengthening the therapeutic alliance via increased trust, empathy and prosociality; and (5) producing benefits beyond core PTSD symptoms, for example reductions in depressive symptoms and improvements in sleep or problematic alcohol use reported in adult studies. Suggested adaptations to the psychotherapeutic model: The authors contrast the primarily non-directive MDMA-AP manual with structured trauma-focused therapies for adolescents and argue for several practical modifications if MDMA-AP is to be trialled with 14–17-year-olds. They recommend stronger emphasis on motivation-building (motivational interviewing and age-appropriate psychoeducation), more deliberate efforts to establish and monitor therapeutic alliance, additional emotion- and behaviour-regulation techniques (borrowing elements from TF-CBT or dialectical-behavioural approaches), and a greater degree of therapist guidance during MDMA sessions—particularly more directive exposure-based work to help organise and integrate traumatic memories. The paper also suggests augmenting post-session integration and practical support (case management, relapse prevention plans) and involving families or caregivers appropriately while respecting adolescents' autonomy and confidentiality. Potential risks particular to adolescents: The authors stress that adult safety data cannot be directly generalised, as recent MDMA-AP trials have involved participants with a mean age near 40. Acute physiological effects at typical therapeutic doses (75–125 mg) include increased heart rate, blood pressure and body temperature; younger adults may show greater heart rate elevation in some reports. Psychological adverse effects noted in adult samples include acute anxiety, transient low mood post-acutely, and rare events related to suicidality (adverse events involving suicidality were reported in a recent Phase III trial, with suicidal behaviour reported only in the placebo arm). Adolescents typically have higher trait neuroticism and emotional reactivity, and rates of self-harm and suicidality are elevated in trauma-exposed youth, so close monitoring would be required. Preclinical literature raises questions about MDMA neurotoxicity at high or repeated doses; animal studies show mixed results and a review concluded that doses below 3 mg/kg in animals produced no clear cognitive impairments, whereas therapeutic human dosing is about 1–2 mg/kg. Nonetheless, direct adolescent human data are absent, so cognitive safety needs study. Misuse potential exists but appears rare in adult trials; given adolescents’ heightened impulsivity and reward sensitivity, there may be an elevated risk that minors will seek MDMA outside clinical settings. Finally, the authors highlight ethical concerns unique to paediatric psychopharmacology and note historical abuses in child research and at least one recent instance of unethical behaviour in adult MDMA research, arguing for stringent ethical safeguards and thorough adverse-event reporting in any adolescent studies.

Kangaslampi and Zijlmans interpret the assembled evidence as supportive of conducting empirical clinical trials of MDMA-AP in adolescents rather than assuming adult findings automatically generalise. They position MDMA-AP as potentially advantageous for adolescents who have difficulty engaging with current trauma-focused therapies, particularly where avoidance, emotional overwhelm, poor therapeutic alliance, or maladaptive trauma-related cognitions impede progress. The authors emphasise that several mechanisms identified in adult research—reduced avoidance, facilitation of reappraisal, enhanced extinction/reconsolidation, and improved therapeutic alliance—could be particularly relevant to the developmental and clinical characteristics of older adolescents. Limitations and uncertainties are repeatedly acknowledged. The paper stresses the dearth of direct adolescent data on dosing, pharmacokinetics, acute and longer-term safety (including cognitive effects), and misuse risk. The authors also acknowledge that many of their suggested psychotherapeutic adaptations are speculative and based on indirect evidence derived from adult MDMA studies and established adolescent trauma therapies; thus comparative or dismantling trials are needed to determine which adaptations are necessary or beneficial. Ethical complexities in paediatric psychopharmacology and the altered conscious state induced by MDMA are highlighted as additional uncertainties demanding careful governance. In terms of implications, the authors call for rigorous, ethically conducted clinical trials in adolescents if MDMA-AP becomes an approved adult treatment, including studies that compare or integrate MDMA with existing evidence-based adolescent PTSD protocols. They caution against off-label use in minors without an evidence base and urge comprehensive adverse-event monitoring, age-appropriate protocol development, and consideration of family involvement, motivation-building, emotion regulation supports, and therapist training to reduce dependence on individual therapist skill.

The authors conclude that, given the burden of untreated PTSD in adolescents and the limitations of current treatments, it is sensible to study MDMA-AP for 14–17-year-olds. They reiterate that adolescence presents both opportunities and challenges for such interventions and that modifications to the psychotherapeutic component may be necessary. Importantly, Kangaslampi and Zijlmans argue against extrapolating adult data to minors or pursuing off-label use; instead, they advocate for ethically robust clinical research to establish safety and efficacy in adolescents, ideally including comparative trials that test adapted psychotherapeutic protocols or combinations with established adolescent treatments.